Insider Selling: Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Moderna Stock Performance

MRNA stock traded down $1.94 during midday trading on Thursday, hitting $148.87. The stock had a trading volume of 13,253,486 shares, compared to its average volume of 11,625,410. The firm has a market capitalization of $59.43 billion, a price-to-earnings ratio of -18.63 and a beta of 1.10. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $176.66. The stock has a 50-day simple moving average of $82.40 and a 200 day simple moving average of $62.12. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.13) EPS. As a group, equities research analysts anticipate that Moderna, Inc. will post -6.09 earnings per share for the current year.

Institutional Investors Weigh In On Moderna

A number of large investors have recently bought and sold shares of MRNA. Louisiana State Employees Retirement System bought a new stake in Moderna during the 1st quarter worth about $899,000. Merck & Co. Inc. acquired a new stake in Moderna in the 2nd quarter valued at about $161,642,545. Bank of New York Mellon Corp bought a new position in shares of Moderna in the second quarter worth about $119,168,000. Contravisory Investment Management Inc. lifted its position in shares of Moderna by 1,387.6% during the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock worth $1,696,000 after purchasing an additional 22,590 shares in the last quarter. Finally, Lingotto Investment Management LLP lifted its position in shares of Moderna by 33.7% during the fourth quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company’s stock worth $14,706,000 after purchasing an additional 125,598 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that Phase 3 INTerpath-001 met its primary recurrence-free-survival endpoint in patients with resected stage IIB–IV melanoma. The result marked the first positive Phase 3 trial for an mRNA-based cancer therapy and significantly strengthened Moderna’s oncology strategy. Moderna and Merck melanoma trial announcement
• Positive Sentiment: The FDA approved Moderna’s mFlusiva mRNA flu vaccine for adults, adding a commercial opportunity beyond COVID-19 and cancer. FDA approves Moderna mRNA flu vaccine
• Positive Sentiment: Brookline Capital Markets raised its 2026–2028 EPS forecasts and maintained a Buy rating, projecting Moderna could reach positive earnings in 2028. Moderna analyst estimates
• Neutral Sentiment: Investor interest remains elevated: Bamco bought roughly 2 million Moderna shares in the second quarter, while options activity and short-squeeze speculation point to continued bullish trading interest. Bamco Moderna investment
• Negative Sentiment: Rothschild & Co. Redburn downgraded Moderna from Neutral to Sell, arguing the cancer-vaccine rally has made the stock overvalued. Its $81 price target implies substantial downside from current levels, despite being raised from $40. Rothschild Moderna downgrade
• Negative Sentiment: GSK advanced a competing mRNA flu vaccine into Phase 3 after reporting stronger immune responses in Phase 2, raising future competitive risk for mFlusiva. GSK mRNA flu vaccine development

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Piper Sandler reissued an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd. Barclays lifted their price objective on Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a report on Monday, August 24th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $130.00 target price on shares of Moderna in a report on Wednesday, August 19th. Citigroup raised their target price on Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research note on Wednesday, August 19th. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and a consensus target price of $76.72.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.